Verrica Pharmaceuticals (VRCA) Stock Forecast, Price Target & Predictions
VRCA Stock Forecast
Verrica Pharmaceuticals stock forecast is as follows: an average price target of $12.00 (represents a 1106.64% upside from VRCA’s last price of $0.99) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
VRCA Price Target
The average price target for Verrica Pharmaceuticals (VRCA) is $12.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $10.00. This represents a potential 1106.64% upside from VRCA's last price of $0.99.
VRCA Analyst Ratings
According to 5 Wall Street analysts, Verrica Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for VRCA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Verrica Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Glen Santangelo | Jefferies | - | - | 6.37% | 1106.64% |
| May 14, 2024 | Oren Livnat | H.C. Wainwright | - | - | 46.44% | 1307.74% |
| Jul 25, 2023 | Serge Belanger | Needham | - | - | 87.97% | 905.53% |
The latest Verrica Pharmaceuticals stock forecast, released on May 14, 2024 by Glen Santangelo from Jefferies, set a price target of $12.00, which represents a 6.37% increase from the stock price at the time of the forecast ($11.28), and a 1106.64% increase from VRCA last price ($0.99).
Verrica Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $13.00 |
| Last Closing Price | $0.99 | $0.99 | $0.99 |
| Upside/Downside | -100.00% | -100.00% | 1207.19% |
In the current month, the average price target of Verrica Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verrica Pharmaceuticals's last price of $0.99. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 02, 2024 | Needham | Buy | Hold | Downgrade |
| May 14, 2024 | Jefferies | Buy | Buy | Hold |
| May 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 25, 2023 | Needham | Buy | Upgrade | |
| Feb 13, 2023 | RBC Capital | Sector Perform | Outperform | Upgrade |
| May 25, 2022 | RBC Capital | Sector Perform | Downgrade |
Verrica Pharmaceuticals's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave VRCA a "Buy" rating, the same as its previous rate.
Verrica Pharmaceuticals Financial Forecast
Verrica Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.99M | $2.92M | $182.00K | $37.00K | $68.00K | $8.32M | $214.00K | $431.00K | - | $12.00M |
| Avg Forecast | $8.01M | $6.13M | $4.31M | $2.11M | $532.75K | $5.26M | $4.58M | $2.81M | $975.25K | $454.07K | $57.60K | $322.00K | $312.50K | $4.33M | $312.50K | $332.40K | $200.00K | $20.37M |
| High Forecast | $10.09M | $7.73M | $5.43M | $2.66M | $671.11K | $6.63M | $4.58M | $2.85M | $1.24M | $454.10K | $72.56K | $405.63K | $393.66K | $4.33M | $312.50K | $332.40K | $200.00K | $24.44M |
| Low Forecast | $6.19M | $4.74M | $3.33M | $1.63M | $411.86K | $4.07M | $4.58M | $2.77M | $700.41K | $454.03K | $44.53K | $248.93K | $241.59K | $4.33M | $312.50K | $332.40K | $200.00K | $16.29M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 10 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 2.04% | 6.42% | 3.16% | 0.11% | 0.22% | 1.92% | 0.68% | 1.30% | - | 0.59% |
Verrica Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $2.81M, with a low forecast of $2.77M, and a high forecast of $2.85M. VRCA's average Quarter revenue forecast represents a 41.21% increase compared to the company's last Quarter revenue of $1.99M (Dec 23).
Verrica Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 10 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $-27.81M | $-23.92M | $-11.62M | $-6.46M | $-5.93M | $1.73M | $-9.00M | $-7.29M | $-10.66M | $103.00K |
| Avg Forecast | $-1.60M | $-1.23M | $-862.40K | $-421.70K | $-106.55K | $-1.05M | $-916.63K | $-561.45K | $-195.05K | $-90.81K | $-11.52K | $-64.40K | $-62.50K | $-865.95K | $-62.50K | $-9.74M | $-40.00K | $174.81K |
| High Forecast | $-1.24M | $-948.41K | $-666.70K | $-326.00K | $-82.37K | $-813.55K | $-916.61K | $-553.13K | $-140.08K | $-90.81K | $-8.90K | $-49.78K | $-48.32K | $-865.95K | $-62.50K | $-7.79M | $-40.00K | $209.77K |
| Low Forecast | $-2.02M | $-1.55M | $-1.09M | $-531.22K | $-134.22K | $-1.33M | $-916.64K | $-569.78K | $-248.25K | $-90.82K | $-14.51K | $-81.12K | $-78.73K | $-865.95K | $-62.50K | $-11.68M | $-40.00K | $139.84K |
| Surprise % | - | - | - | - | - | - | - | - | 142.58% | 263.37% | 1008.42% | 100.28% | 94.91% | -2.00% | 144.07% | 0.75% | 266.53% | 0.59% |
1 analysts predict VRCA's average Quarter EBITDA for Dec 22 to be $-62.50K, with a high of $-48.32K and a low of $-78.73K. This is -103.62% lower than Verrica Pharmaceuticals's previous annual EBITDA (Sep 22) of $1.73M.
Verrica Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 10 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $-25.11M | $-24.80M | $-10.99M | $-6.09M | $-5.65M | $-1.28M | $-11.21M | $-9.53M | $-11.78M | $-936.00K |
| Avg Forecast | $-5.85M | $-6.55M | $-7.49M | $-9.36M | $-14.04M | $-17.61M | $-19.37M | $-20.92M | $-26.30M | $-16.91M | $-9.84M | $-8.92M | $-8.96M | $-4.88M | $-14.88M | $-11.35M | $-19.25M | $-1.59M |
| High Forecast | $-4.12M | $-4.62M | $-5.28M | $-6.60M | $-9.90M | $-12.42M | $-13.66M | $-14.75M | $-24.07M | $-11.92M | $-6.93M | $-6.29M | $-6.31M | $-4.88M | $-14.88M | $-9.08M | $-19.25M | $-1.27M |
| Low Forecast | $-7.83M | $-8.77M | $-10.02M | $-12.52M | $-18.78M | $-23.56M | $-25.91M | $-27.98M | $-28.54M | $-22.62M | $-13.16M | $-11.93M | $-11.98M | $-4.88M | $-14.88M | $-13.62M | $-19.25M | $-1.91M |
| Surprise % | - | - | - | - | - | - | - | - | 0.95% | 1.47% | 1.12% | 0.68% | 0.63% | 0.26% | 0.75% | 0.84% | 0.61% | 0.59% |
Verrica Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRCA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Verrica Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 10 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $17.00M | $20.05M | $5.94M | $4.32M | $3.19M | $3.92M | $5.17M | $5.12M | $7.28M | $6.58M |
| Avg Forecast | $24.68M | $18.90M | $13.29M | $6.50M | $1.64M | $16.21M | $14.12M | $8.65M | $3.01M | $1.40M | $177.49K | $992.23K | $962.96K | $13.27M | $957.86K | $1.02M | $613.03K | $11.16M |
| High Forecast | $31.09M | $23.81M | $16.74M | $8.18M | $2.07M | $20.42M | $14.12M | $8.78M | $3.82M | $1.40M | $223.59K | $1.25M | $1.21M | $13.27M | $957.86K | $1.02M | $613.03K | $13.40M |
| Low Forecast | $19.08M | $14.61M | $10.27M | $5.02M | $1.27M | $12.53M | $14.12M | $8.52M | $2.16M | $1.40M | $137.21K | $767.07K | $744.44K | $13.27M | $957.86K | $1.02M | $613.03K | $8.93M |
| Surprise % | - | - | - | - | - | - | - | - | 5.66% | 14.33% | 33.45% | 4.35% | 3.31% | 0.30% | 5.40% | 5.02% | 11.88% | 0.59% |
Verrica Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $8.65M, based on 1 Wall Street analysts, with a range of $8.52M to $8.78M. The forecast indicates a -49.10% fall compared to VRCA last annual SG&A of $17.00M (Dec 23).
Verrica Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 10 | 11 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.00 | $-0.14 | $-0.14 | $-0.03 | $-0.41 | $-0.35 | $-0.43 | $-0.04 |
| Avg Forecast | $-0.13 | $-0.14 | $-0.16 | $-0.20 | $-0.30 | $-0.38 | $-0.41 | $-0.45 | $-0.56 | $-0.36 | $-0.21 | $-0.19 | $-0.19 | $-0.10 | $-0.32 | $-0.33 | $-0.41 | $-0.35 |
| High Forecast | $-0.09 | $-0.10 | $-0.11 | $-0.14 | $-0.21 | $-0.27 | $-0.29 | $-0.32 | $-0.51 | $-0.25 | $-0.15 | $-0.13 | $-0.13 | $-0.10 | $-0.32 | $-0.33 | $-0.41 | $-0.35 |
| Low Forecast | $-0.17 | $-0.19 | $-0.21 | $-0.27 | $-0.40 | $-0.50 | $-0.55 | $-0.60 | $-0.61 | $-0.48 | $-0.28 | $-0.25 | $-0.26 | $-0.10 | $-0.32 | $-0.33 | $-0.41 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.74% | 0.73% | 0.30% | 1.28% | 1.05% | 1.04% | 0.12% |
According to undefined Wall Street analysts, Verrica Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRCA previous annual EPS of $NaN (undefined).
Verrica Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | - | - | 1274.05% | Buy |
| VRCA | Verrica Pharmaceuticals | - | - | 1112.12% | Buy |
| VIGL | Vigil Neuroscience | - | - | 244.83% | Buy |
| LRMR | Larimar Therapeutics | - | - | 230.03% | Buy |
| PLRX | Pliant Therapeutics | - | - | 205.93% | Buy |
| ARQT | Arcutis Biotherapeutics | - | - | 205.72% | Buy |
| FENC | Fennec Pharmaceuticals | - | - | 196.05% | Buy |
| ABOS | Acumen Pharmaceuticals | - | - | 195.36% | Buy |
| FIXX | Q32 Bio | - | - | 190.32% | Buy |
| NUVB | Nuvation Bio | - | - | 141.07% | Buy |
| CNTB | Connect Biopharma | - | - | 50.00% | Buy |
| ASND | Ascendis Pharma | - | - | 46.53% | Buy |
| EWTX | Edgewise Therapeutics | - | - | 39.75% | Buy |
| DICE | DICE Therapeutics | - | - | 26.18% | Buy |
| CRNX | Crinetics Pharmaceuticals | - | - | 25.12% | Buy |
| ETON | Eton Pharmaceuticals | - | - | 15.76% | Buy |
| VRNA | Verona Pharma | - | - | -12.75% | Buy |
| KDNY | Chinook Therapeutics | - | - | -25.72% | Buy |